HCAR2 Protein, Human (Cell-Free, His)

HCAR2 protein, a high-affinity receptor for nicotinic acid and (D)-beta-hydroxybutyrate, induces increased adiponectin secretion and reduced lipolysis through G(i)-protein-mediated adenylyl cyclase inhibition. This requires nicotinic acid doses exceeding typical dietary levels. HCAR2 also mediates nicotinic acid-induced apoptosis in neutrophils. Upon nicotinic acid activation, reduced cAMP levels potentially influence cAMP-dependent protein kinase A activity and target protein phosphorylation, leading to neutrophil apoptosis. Relative potency for displacing nicotinic acid binding: 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide. HCAR2 Protein, Human (Cell-Free, His) is the recombinant human-derived HCAR2 protein, expressed by E. coli Cell-free, with C-6*His labeled tag. The total length of HCAR2 Protein, Human (Cell-Free, His) is 363 a.a., with molecular weight of 42.7 kDa.

HCAR2 protein serves as a high-affinity receptor for both nicotinic acid (niacin) and (D)-beta-hydroxybutyrate, orchestrating increased adiponectin secretion and reduced lipolysis through G(i)-protein-mediated inhibition of adenylyl cyclase. This pharmacological impact requires nicotinic acid doses that surpass those typically obtained from a regular diet. Additionally, HCAR2 mediates nicotinic acid-induced apoptosis in mature neutrophils. Upon receptor activation by nicotinic acid, a decrease in cAMP levels ensues, potentially influencing the activity of cAMP-dependent protein kinase A and the phosphorylation of target proteins, ultimately leading to neutrophil apoptosis. The relative potency for displacing nicotinic acid binding follows the order: 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.

Human

E. coli Cell-free

C-6*His

Q8TDS4 (M1-P363)

338442

MNRHHLQDHFLEIDKKNCCVFRDDFIVKVLPPVLGLEFIFGLLGNGLALWIFCFHLKSWKSSRIFLFNLAVADFLLIICLPFLMDNYVRRWDWKFGDIPCRLMLFMLAMNRQGSIIFLTVVAVDRYFRVVHPHHALNKISNRTAAIISCLLWGITIGLTVHLLKKKMPIQNGGANLCSSFSICHTFQWHEAMFLLEFFLPLGIILFCSARIIWSLRQRQMDRHAKIKRAITFIMVVAIVFVICFLPSVVVRIRIFWLLHTSGTQNCEVYRSVDLAFFITLSFTYMNSMLDPVVYYFSSPSFPNFFSTLINRCLQRKMTGEPDNNRSTSVELTGDPNKTRGAPEALMANSGEPWSPSYLGPTSP

42.7 kDa

Greater than 90% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.